Inclusion of BLIMP-1+ effector regulatory T cells improves the Immunoscore in a cohort of New Zealand colorectal cancer patients: a pilot study

Ward-Hartstonge, KA; McCall, JL; McCulloch, TR; Kamps, AK; Girardin, A; Cretney, E; Munro, FM; Kemp, RA

Author(s): Ward-Hartstonge, KA; McCall, JL; McCulloch, TR; Kamps, AK; Girardin, A; Cretney, E; Munro, FM; Kemp, RA;
Details: Publication Year 2017-01-23,Volume 66,Issue #4,Page 515-522
Journal Title: Cancer Immunol Immunother
Publication Type: Journal Article in press
Abstract: Analysis of tumour-infiltrating T cells in colorectal cancer can predict disease-free survival. The Immunoscore, obtained by quantifying tumour-infiltrating CD3+ and CD8+ T cells, may improve current staging. Effector regulatory T cells are a potently suppressive subset in mice and, while present in human colorectal cancer, their role in patient outcome is unknown. Immunofluorescence was used to analyse immune cell infiltrates in patients with early (stage II) colorectal cancer with (n = 13) and without (n = 19) recurrent disease. CD3 and CD8 were used for the Immunoscore; FOXP3, BLIMP-1 and CD3 to identify effector regulatory T cells. Patients with high Immunoscores had increased disease-free survival compared to patients with low Immunoscores (Log-rank test p < 0.01). Prediction of outcome was further improved by stratifying patients with a low Immunoscore according to CD3+FOXP3+BLIMP-1+ cell infiltration at the invasive margin. Patients with a low Immunoscore and high infiltrate of CD3+FOXP3+BLIMP-1+ cells tended to have better disease-free survival than patients with low Immunoscore and low infiltrate of CD3+FOXP3+BLIMP-1+ cells. Patients with a high Immunoscore had better disease-free survival than patients with a low Immunoscore and low infiltrate of CD3+ FOXP3+ BLIMP-1+ cells (Log-rank test p < 0.001). These results indicate that tumour infiltration with effector regulatory T cells improves the prognostic value of the Immunoscore and implies that these cells may play a role in colorectal cancer patient outcome.
Research Division(s): Molecular Immunology
PubMed ID: 28116480
Publisher's Version: https://doi.org/10.1007/s00262-016-1951-1
NHMRC Grants: NHMRC/1047313,
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2017-04-06 09:27:15

Last Modified: 2017-04-07 02:27:02